Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma.
about
Risk factors for etiology and prognosis of mantle cell lymphomaIdentification of novel mutations and sequence variation in the Zellweger syndrome spectrum of peroxisome biogenesis disordersAntiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphomaParallel gene expression profiling of mantle cell lymphoma - how do we transform 'omics data into clinical practiceThe genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cellsInduction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma.Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling.Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphomaHDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphomaDevelopment of a murine model for blastoid variant mantle-cell lymphomaThe impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53The spectrum of ATM missense variants and their contribution to contralateral breast cancerMolecular pathogenesis of mantle cell lymphoma.Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma.Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature.Targeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles.Genomic deletion and promoter methylation status of Hypermethylated in Cancer 1 (HIC1) in mantle cell lymphoma.Colorectal Choriocarcinoma in a Patient with Probable Lynch Syndrome.Gene mutations and actionable genetic lesions in mantle cell lymphoma.ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib.Will new drugs change the standard of care for patients with mantle cell lymphoma?Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop.Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation.DNA damage response and hematological malignancy.Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repairGene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia.Proteomics analyses of human optic nerve head astrocytes following biomechanical strain.A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress.The awakening of the CDK10/Cyclin M protein kinase.Ataxia-Telangiectasia Mutated (ATM) Protein Signaling Participates in Development of Pulmonary Arterial Hypertension in Rats.ATM deficiency augments constitutively nuclear cyclin D1-driven genomic instability and lymphomagenesis.Novel therapies for aggressive B-cell lymphomaThe potential of copy number gains and losses, detected by array-based comparative genomic hybridization, for computational differential diagnosis of B-cell lymphomas and genetic regions involved in lymphomagenesis.Histone deacetylase inhibitors as cancer therapeutics.CCMCL1: a new model of aggressive mantle cell lymphoma.TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.Apoptosis and expression of the Bcl-2 family of proteins and P53 in human pancreatic ductal adenocarcinoma.
P2860
Q26858960-593FCA6A-B53F-49DD-B067-5BC78F6247B9Q28304924-B133BFD3-F890-443E-8A61-E30FB8F85AFCQ30498194-6C371EF4-9477-49C9-BAF0-044F0DE87963Q31164228-27AEF8ED-9613-4E69-85DD-CB2BB28FE104Q33585273-18DAD246-1F7A-419F-AB92-95E180EABFC7Q33934010-6CD1518C-9A85-4B1B-9307-908B82EDFFDDQ34074921-B740E81A-6973-467B-B499-34EAB2071D4DQ34135450-21CA8064-7E3A-45AD-AC1D-C62E2CB77702Q35483623-07D15A9F-FB71-467D-90CA-1F386F0BEF66Q35828767-5C5B2E7F-2954-46AA-AC64-895B6D317C6FQ36216258-6B57852A-605B-490A-8E92-D0E04183967BQ36238650-251DE872-2361-48CB-8C99-3018A1783652Q36267279-8786B3CE-B849-4728-AF49-27A9B11A992FQ36290246-F9F68BAF-0EFE-49EF-A5C0-A99495A73B82Q36447932-E0616214-6758-4D1E-84A3-8A12CCE26237Q36629194-E1BD732F-B415-4B9E-85CD-9BEF5BDF6954Q36889248-766F32F1-F441-46A2-AF7E-F198C74352B1Q37269010-3B7ACA3E-ED22-442E-B79E-CF07E65EB65DQ37447203-BAA5A992-DA0C-4DD0-93E1-6391F1BB27C6Q37629080-850D3120-B0B0-4345-A716-4680EF85C027Q37633188-EE83F495-946E-4F43-B4D6-499ED6624B13Q38658549-C2350C21-8E3A-4A4E-9445-75162C8ACFE0Q38763829-7D7E3F85-215D-474F-9AA4-C98BBFA60058Q38819164-B10C0C30-F88C-47E6-9BC9-BACFDB41CF28Q38840443-93C8D1D7-59C0-45DF-AC1C-A299AF62A8D6Q39218048-BA245E34-A43E-4418-9CAE-28771CACC54AQ39406673-A333E866-8CE4-4FAE-9BCB-E224E9CF8A2DQ39695835-97978CF7-1B68-47DF-8F98-2D7DC37D218CQ39819083-757FF51E-E68F-41E3-960E-53B3D4C059D4Q41044103-852AD0E6-7B8B-4221-A746-A991849CD505Q41362934-40699D91-3177-4789-8FCA-689F33491267Q41472998-79D69858-E90E-49EC-8753-AE923054F9A0Q41689585-7B41A625-3966-4F4C-90F8-DF0ADEC85C11Q41893268-9BE12460-E7F7-461D-B0AD-81AE661371FCQ42011578-8A9190EA-1B09-4C51-9FB9-B0A1765FC302Q42040698-B00CF1F5-D81C-4514-A7A6-BAF3272B2691Q42106883-228ABB52-9396-4432-9012-3D300F42E716Q42553373-1CB383AA-1A29-475D-A489-C657566FA74BQ44418379-77A803AA-6FE8-4B91-86B5-D0B1B9954F8CQ51511748-BD6BC5EE-B4F5-4307-8E74-C2CFBACD59D8
P2860
Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Mutation and genomic deletion ...... files in mantle cell lymphoma.
@ast
Mutation and genomic deletion ...... files in mantle cell lymphoma.
@en
Mutation and genomic deletion status of ataxia telangiectasia mutated
@nl
type
label
Mutation and genomic deletion ...... files in mantle cell lymphoma.
@ast
Mutation and genomic deletion ...... files in mantle cell lymphoma.
@en
Mutation and genomic deletion status of ataxia telangiectasia mutated
@nl
prefLabel
Mutation and genomic deletion ...... files in mantle cell lymphoma.
@ast
Mutation and genomic deletion ...... files in mantle cell lymphoma.
@en
Mutation and genomic deletion status of ataxia telangiectasia mutated
@nl
P2093
P2860
P50
P356
P1476
Mutation and genomic deletion ...... files in mantle cell lymphoma.
@en
P2093
Andreas Rosenwald
Brian L Pike
Chiranjib Dasgupta
Elaine S Jaffe
German Ott
James C Lynch
Joseph G Hacia
Louis M Staudt
Lynette M Smith
P2860
P304
P356
10.1073/PNAS.0510441103
P407
P50
P577
2006-02-03T00:00:00Z